Authors
Bingke Chen, Yuping Zhao, Mao Zhang, Hengping Li
Published in
Zhonghua nan ke xue = National journal of andrology. Volume 32. Issue 5. Pages 446-452.
Abstract
Prostate cancer (PCa) is a common malignant tumor in the male urogenital system. In China, its incidence and mortality rates have shown a significant upward trend, seriously threatening men's health. Androgen deprivation therapy remains the cornerstone of PCa treatment. However, a subset of patients inevitably progresses to castration-resistant prostate cancer (CRPC) or metastatic castration-resistant prostate cancer(mCRPC), for which therapeutic options are limited and prognosis remains poor. Therefore, novel biomarkers and therapeutic strategies are urgently needed. Glycosylation, the most structurally complex post-translational modification of proteins, is extensively involved in physiological and pathological processes. Aberrant glycosylation not only affects the specificity and sensitivity of prostate-specific antigen (PSA) but also plays a crucial role in drug resistance, metastasis, and immune evasion in CRPC. Multiple studies have demonstrated that alterations in PSA glycoforms, serum N-glycan patterns, and dysregulation of glycosyltransferases hold potential value for early diagnosis and risk stratification. Moreover, core fucosylation and O-GlcNAcylation promote CRPC progression by modulating androgen receptor signaling, epithelial-mesenchymal transition, and the tumor microenvironment. This review summarizes recent advances in the study of glycosylation in PCa, particularly in CRPC, and discusses its potential applications in early diagnosis, prognostic assessment, and therapeutic strategies, providing new insights for precision medicine in prostate cancer.
PMID:
43012236
Bibliographic data and abstract were imported from PubMed on 11 Nov 2026.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 2
- Comments 0